Oncolys Biopharma advances OBP-301 manufacturing, expands OBP-801 patent scope

Oncolys Biopharma announced the start of GMP compliant formulation manufacturing for OBP-301, an oncolytic virus slated for release in 2026. This follows the completion of GMP drug substance manufacturing by Henogen in Belgium, preparing for domestic import and delivery upon approval. Oncolys expects to receive an advance payment for OBP-301 product from Fujifilm Toyama Chemical Co., Ltd. in 2025, to be recognized as revenue upon the product's market launch.

Separately, Oncolys Biopharma confirmed the expansion of its patent scope for OBP-801 in ophthalmology. Following a 2024 patent for treating glaucoma and age-related macular degeneration (AMD), a divisional application broadened the claims for AMD, increasing the maximum dosage limit by 150 times and extending patent validity until July 2039. This expansion enhances development flexibility for a disease affecting approximately 700,000 people in Japan, with OBP-801 showing potential for both wet and dry AMD.

The company anticipates a minor impact on its December 2025 fiscal year performance from the patent extension.